MTOR and breast carcinoma: Substantial evidence indicates that PIK3CA mutations lead to aberrant activation of the PI3K/AKT/mTOR signaling pathway, contributing to endocrine therapy resistance in breast cancer and closely correlating with poor prognosis (15–17).